Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation
Smoking cessation generates large gains in life expectancy. This mathematical model demonstrated that immediate cytisine availability, even if used successfully by only a small fraction of people who smoke, could produce major public health benefits. Given the need for new tobacco cessation pharmacotherapy options, the magnitude of cytisine's potential public health benefits, and the morbidity and mortality associated with delay in its availability, a timely review of cytisine for approval in the US is warranted.
Authors
- A. David Paltiel (ORCID: https://orcid.org/0000-0002-4861-3290)
- Krishna P. Reddy (ORCID: https://orcid.org/0000-0002-1832-2193)
- Nancy A. Rigotti (ORCID: https://orcid.org/0000-0002-2223-1657)
- Kenneth A. Freedberg (ORCID: https://orcid.org/0000-0003-3143-7822)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1001/jamahealthforum.2024.2647
- Citations
- 4
- Primary Topic
- Smoking Behavior and Cessation
- Type
- article
- Field-Weighted Citation Impact
- 1.31